A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure-Reference-Cited by-同舟云学术

A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure

Published:1992-01 Issue:1 Volume:123 Page:95-103
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Katz Stuart D.,Kubo Spencer H.,Jessup Mariell,Brozena Suzanne,Troha Janice M.,Wahl Janice,Cohn Jay N.,Sonnenblick Edmund H.,LeJemtel Thierry H.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference27 articles.

1. Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man;LeJemtel;Circulation,1979

2. Hemodynamic assessment of amrinone, a new inotropic agent;Benotti;N Engl J Med,1978

3. Evaluation of a new bipyridine inotropic agent—milrinone—in patients with severe congestive heart failure;Baim;N Engl J Med,1983

4. The acute hemodynamic effects of a new agent MDL 17043 in the treatment of congestive heart failure;Uretsky;Circulation,1983

5. Long-term administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial;Massie;Circulation,1985

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Treatments of Hypertrophic Cardiomyopathy in GDMT for Heart Failure: A State-of-art Review;Current Problems in Cardiology;2023-09

2. Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF;Circulation: Heart Failure;2022-05

3. A pilot study investigating the effect of pimobendan on the cardiac rhythm and selected echocardiographic parameters of healthy cats;Journal of Veterinary Cardiology;2021-06

4. A Review on Role of the Calcium Sensitive Inotropic Agent, Levosimendan and Its Metabolites;Mini-Reviews in Medicinal Chemistry;2018-09-13

5. Insights from Second-Line Treatments for Idiopathic Dilated Cardiomyopathy;Journal of Cardiovascular Development and Disease;2017-08-23